- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00921726
Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults
Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It is very likely that during an influenza pandemic, intravenous zanamivir will be used in combination with oseltamivir. Although the potential for a drug interaction between the two drugs is very low, the likelihood of coadministration combined with the common route of renal clearance of both drugs and the current lack of information on the organic anion transporter polypeptides (OATP) inhibition potential of zanamivir in vivo warrants verification of a lack of an interaction. This study will provide clinical guidance for the use of intravenous zanamivir in settings where oral oseltamivir is commonly used, such as areas in which human cases of H5N1 have been reported.
The total duration of study participation is approximately 13 weeks. Each participant will have a screening visit, four treatment steps, and a follow-up visit. The screening visit to determine enrollment eligibility will be conducted within 45 days prior to receiving the first dose. Participants will be randomized to receive either Regimen A or B for Step 1. Participants who received Regimen A will receive Regimen B in Step 2 and vice versa. After completing Step 2, all participants will continue with Regimens C and D, consecutively, in Steps 3 and 4, with at least 3 days between each step. A follow-up visit will occur 7-10 days after completing the last treatment assessments or withdrawing from the study.
Regimen A consists of continuous intravenous zanamivir infusion (800 mg) for 16 hours. Regimen B consists of 150 mg oral oseltamivir tablets taken five times over 3 days. Regimen C consists of 150 mg oral oseltamivir tablets taken five times over 3 days plus continuous intravenous zanamivir infusion (3600 mg) for 36 hours. Regimen D consists of 150 mg oral oseltamivir tablets taken five times over 3 days plus intermittent intravenous zanamivir infusion received in five 30 minute intervals (3000 mg total).
Blood and urine collection, vital signs, pharmacokinetic sampling, adverse event assessment, and pregnancy test for females will occur at each step in the study. The follow-up visit will involve blood and urine collection, vital signs, adverse event assessment, and pregnancy test for females.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Salaya, Thailand, 73170
- Mathidol University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Good general health
- Body mass index between 17 - 32 kg/m^2
- Body weight of at least 37 kg
- Able to read, comprehend, and write at a sufficient level to complete study-related materials
- Normal ECG with QTC less than 450 msec as judged by cardiologist
- Willing and ability to comply with the study protocol for the duration of the trial
Exclusion Criteria:
- History of cardiac disease or abnormality. More information on this criterion can be found in the protocol.
- Family history of sudden cardiac death
- HIV-infected
- Hepatitis C virus infected
- Positive for hepatitis B surface antigen (HBsAg)
- History of renal disease, hepatic disease, and/or cholecystectomy
- Evidence of active substance abuse
- History of alcohol or substance abuse or dependence within 6 months prior to study entry. More information on this criterion can be found in the protocol.
- Use of prescription or non-prescription drugs, except paracetamol, at doses of up to 2 g/day. More information on this criterion can be found in the protocol.
- Use of FluMist, inactivated influenza vaccine, or any other anti-influenza antiviral medications within 14 days prior to study entry
- Participated in a clinical trial and received a drug or new chemical entity within 30 days or five half-lives prior to study entry.
- Unwilling to abstain from ingesting alcohol within 48 hours prior to study entry until collection of the final pharmacokinetic sample during each period
- Donated blood to the extent that participation in this study would result in excess of 300 mL donated within a 30 day period
- History of allergy to the study drug or drugs of this class. More information on this criterion can be found in the protocol.
- Unstable medical condition that, in the opinion of the investigator, would interfere with the study
- Anyone that, in the opinion of the investigator, has a risk of non-compliance with study procedures
- AST or ALN of at least 1.5 ULN
- Certain abnormal laboratory values
- Agree to use effective methods of birth control. More information on this criterion can be found in the protocol.
- Pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Participants will receive treatment in the following order: Study Regimens A, B, C, D
|
Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
Other Names:
150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
Other Names:
|
Experimental: 2
Participants will receive treatment in the following order: Study Regimens B, A, C, D
|
Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
Other Names:
150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Oseltamivir carboxylate Cmax and AUC (0-12)
Time Frame: Throughout study
|
Throughout study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Zanamivir Cmax and AUC (0-12) for continuous infusion and Zanamivir Cmax, AUC (-12), and C12 for intermittent infusions
Time Frame: Throughout study
|
Throughout study
|
Oseltamivir Cmax, AUC (0-12), and C12
Time Frame: Throughout study
|
Throughout study
|
Oseltamivir carboxylate AUC (0-24), C12, delta-z, and t(1/2)
Time Frame: Throughout study
|
Throughout study
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sasithon Pukrittayakamee, MD, Mathidol University, Thailand
Publications and helpful links
General Publications
- Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. doi: 10.1016/j.antiviral.2008.01.003. Epub 2008 Feb 4.
- Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, Yingsakmongkon S, Hirai G, Sodeoka M, von Itzstein M, Miyagi T. Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrob Agents Chemother. 2008 Oct;52(10):3484-91. doi: 10.1128/AAC.00344-08. Epub 2008 Aug 11.
- Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, Nicholson K. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess. 2009 Feb;13(11):iii, ix-xii, 1-246. doi: 10.3310/hta13110.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SEA 003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Virus Diseases
-
Institute of Tropical Medicine, BelgiumCompletedTransmission | Zika Virus | Zika Virus Disease | Virus SheddingBelgium
-
TakedaCompletedFlavivirus Infections | Healthy Participants | Virus, Zika | Zika Virus DiseaseUnited States, Puerto Rico
-
U.S. Army Medical Research and Development CommandActive, not recruiting
-
Emergent BioSolutionsCompletedZika Virus Infection | Zika Virus DiseaseCanada
-
U.S. Army Medical Research and Development CommandCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHealthy | Epstein Barr Virus InfectionUnited States
-
Valneva Austria GmbHEmergent BioSolutionsCompletedZika Virus Infection | Zika VirusUnited States
-
Merck Sharp & Dohme LLCCompletedVaricella Virus Infection
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsUnknown
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Zhongshan People's Hospital, Guangdong, ChinaRecruiting
Clinical Trials on Zanamivir
-
GlaxoSmithKlineCompletedInfluenza, Human
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineWithdrawn
-
GlaxoSmithKlineCompletedInfluenza, HumanAustralia, Taiwan, Korea, Republic of, United States, Belgium, Canada, Germany, South Africa, Spain, United Kingdom, New Zealand, Thailand, India, China, Brazil, Hong Kong, Slovakia, Russian Federation, Denmark, Mexico, Czechia, H... and more
-
GlaxoSmithKlineCompletedInfluenza, HumanUnited States, Spain, France, Australia, South Africa, United Kingdom, Thailand, Hong Kong, Canada, Russian Federation, Japan, Norway, Brazil
-
Assistance Publique - Hôpitaux de ParisGlaxoSmithKline; Hoffmann-La RocheTerminated
-
GlaxoSmithKlineCompletedInfluenza, HumanUnited States
-
University of OxfordNational Institute of Allergy and Infectious Diseases (NIAID)Completed